(2R,3S,4S,5R)-2-(6-(Dimethylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol | 7770-17-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (2R,3S,4S,5R)-2-(6-(Dimethylamino)-9H-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol
• 英文别名: (2R,3S,4S,5R)-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 7770-17-4
• 化学式: C₁₂H₁₇N₅O₄
• 分子量: 295.298
• InChiKey: WVGPGNPCZPYCLK-QRKAXHLRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  117
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• Therapeutic azide compounds
  申请人：University of Georgia Research Foundation, Inc.

  公开号：US20010036930A1

  公开（公告）日：2001-11-01

  Pharmaceutical prodrug compositions are provided comprising azide derivatives of drugs which are capable of being converted to the drug in vivo. Azide derivatives of drugs having amine, ketone and hydroxy substituents are converted in vivo to the corresponding drugs, increasing the half-life of the drugs. In addition azide prodrugs are often better able to penetrate the blood-brain barrier than the corresponding drugs. Especially useful are azide derivatives of cordycepin, 2′-F-ara-ddI, AraA, acyclovir, penciclovir and related drugs. Useful azide prodrugs are azide derivatives of therapeutic alicyclic amines, ketones, and hydroxy-substituted compounds, including aralkyl, heterocyclic aralkyl, and cyclic aliphatic compounds, where the amine or oxygen moiety is on the ring, or where the amine or oxygen moiety is on an aliphatic side chain, as well as therapeutic purines and pyrimidines, nucleoside analogs and phosphorylated nucleoside analogs.

  提供了药物前药组成物，其中包括具有可在体内转化为药物的药物的偶氮衍生物。具有胺基，酮基和羟基取代基的药物的偶氮衍生物在体内转化为相应的药物，增加了药物的半衰期。此外，偶氮前药通常比相应的药物更能穿过血脑屏障。特别有用的是cordycepin，2'-F-ara-ddI，AraA，acyclovir，penciclovir和相关药物的偶氮衍生物。有用的偶氮前药是治疗性脂环烷胺，酮和羟基取代化合物的偶氮衍生物，包括芳基烷基，杂环芳基烷基和环状脂肪族化合物，其中胺基或氧原子基团位于环上，或胺基或氧原子基团位于脂肪侧链上，以及治疗性嘌呤和嘧啶，核苷类似物和磷酸化核苷类似物。
• Antiviral compounds
  申请人：THE WELLCOME FOUNDATION LIMITED

  公开号：EP0294114A2

  公开（公告）日：1988-12-07

  The present invention relates to certain substituted purine arabinosides and their pharmaceutically acceptable derivatives especially esters and their use in the treatment and prophylaxis of varicella zoster virus and cytomegalovirus infections. The invention also includes pharmaceutical formulations and processes for the preparation of such compounds.

  本发明涉及某些取代的嘌呤阿拉伯苷及其药学上可接受的衍生物，特别是酯类，以及它们在治疗和预防水痘带状疱疹病毒和巨细胞病毒感染中的用途。本发明还包括制备此类化合物的药物制剂和工艺。
• MOLECULAR CONSTRUCTS WITH A CARCINOEMBRYONIC ANTIGEN (CEA) TRANSCRIPTIONAL REGULATORY SEQUENCE
  申请人：——

  公开号：US20020055482A1

  公开（公告）日：2002-05-09

  Novel molecular chimaeras produced by recombinant DNA techniques are described. They comprise a target-tissue specific transcriptional regulatory sequence (TRS) linked and controlling the expression of a heterologous enzyme, for example Varicella Zoster Virus Thymidine Kinase (VZV TK) or non-mammaliam Cytosine Deaminase (CD). A molecular chimaera is packaged into a synthetic retroviral particle that is capable of infecting mammalian tissue. This, in turn, may be administered to a host, and the TRS will be selectively transcriptionally activated in the target tissue (for example cancerous cells). Administration of compounds that are selectively metabolised by the enzyme produce cytotoxic or cytostatic metabolites in situ thereby selectively killing or arresting the growth of the target cells.

  本文描述了通过 DNA 重组技术生产的新型分子嵌合体。它们包括一个目标组织特异性转录调控序列（TRS），该序列连接并控制着异源酶的表达，例如水痘带状疱疹病毒胸苷激酶（VZV TK）或非哺乳动物胞嘧啶脱氨酶（CD）。分子嵌合体被包装成能够感染哺乳动物组织的合成逆转录病毒颗粒。反过来，可将其施用给宿主，TRS 将在靶组织（例如癌细胞）中选择性地转录激活。施用被酶选择性代谢的化合物会在原位产生细胞毒性或细胞抑制性代谢产物，从而选择性地杀死或抑制靶细胞的生长。
• THERAPEUTIC AZIDE COMPOUNDS
  申请人：UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.

  公开号：EP0852499A1

  公开（公告）日：1998-07-15
• US5424295A
  申请人：——

  公开号：US5424295A

  公开（公告）日：1995-06-13